证券代码：301258 证券简称：富士莱 公告编号：2025-034 苏州富士莱医药股份有限公司 回购报告书 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 1、回购股份方案的主要内容：苏州富士莱医药股份有限公司（以下简称"公 司"）拟使用自有资金以集中竞价方式回购公司人民币普通股（A 股），回购的 公司股份将在未来适宜时机用于实施股权激励计划或员工持股计划。本次回购股 份资金总额不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含 本数），回购价格不超过人民币 40.00 元/股（含，未超过公司董事会审议通过回 购股份决议前三十个交易日公司股票交易均价的 150%）。按回购价格上限 40.00 元/股测算，预计回购股份数量为 500,000 股至 1,000,000 股，占公司目前总股本 比例为 0.55%至 1.09%。回购期限自公司董事会审议通过本次回购股份方案之日 起不超过 12 个月。 2、回购股份方案的审议程序：2025 年 7 月 7 日，公司召开第四届董事会第 十九次会议、第四届监事会第十八次会议，审议通过 ...

富士莱今日上涨10.30%，全天换手率46.85%，成交额5.97亿元，振幅19.94%。龙虎榜数据显示，机构净 卖出779.56万元，营业部席位合计净卖出14.80万元。 深交所公开信息显示，当日该股因日换手率达46.85%上榜，机构专用席位净卖出779.56万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.37亿元，其中，买入成交额为6459.65 万元，卖出成交额为7254.01万元，合计净卖出794.36万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖三，买入金额304.00万元，卖出金 额1083.56万元，合计净卖出779.56万元。 资金流向方面，今日该股主力资金净流入3986.50万元，其中，特大单净流入5823.32万元，大单资金净 流出1836.82万元。近5日主力资金净流入3903.31万元。（数据宝） 富士莱7月8日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 14 ...

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with circuit board, CRO, and consumer electronics manufacturing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. Pharmaceutical Sector - The pharmaceutical sector experienced a strong opening, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Notable stocks included Lianhuan Pharmaceutical, which achieved a two-day limit up, and several others like Weixin Kang and Ha Sanlian hitting the daily limit [7][8]. - Fujilai (301258) surged to a limit up of 20% to reach a price of 39.28 CNY per share shortly after the market opened [8][9]. PCB Sector - PCB (Printed Circuit Board) stocks continued to strengthen, with companies like International Composite Materials and Yidong Electronics hitting the daily limit. Jin'an Guoji achieved a four-day limit up, while Honghe Technology recorded four limit ups in six days [12][13]. - The demand for high-end PCBs is rapidly increasing due to AI computing needs, leading to a significant supply-demand gap in AI PCBs this year. ASIC chip growth is expected to be the main driver of incremental demand for high-end PCBs by 2026 [14][15]. Company-Specific News - Ruisi Kanda faced a trading halt with a limit down of 9.95% due to allegations of information disclosure violations, leading to criminal measures against its executives [17][20]. - ST Huaming also experienced a limit down of 20.03% following administrative penalties for false disclosures in its financial reports [20].

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant developments, including management changes, stock trading fluctuations, and major contracts, which may present investment opportunities and risks for investors [2]. Group 1: Management Changes and Legal Issues - Scanda's chairman and general manager, Li Yuejie, along with director Zhu Chuncheng, have been subjected to criminal coercive measures due to alleged violations related to information disclosure [3]. - Longhong High-Tech is planning to acquire 100% equity of Guangxi Changke, leading to a stock suspension for up to 10 trading days [6]. Group 2: Stock Trading and Performance - New Asia Electronics reported abnormal stock trading with a cumulative price deviation exceeding 20% over three days, while confirming that its operations are normal and consistent with previously disclosed share reduction plans [5]. - ST Tiexin announced the removal of risk warnings and a name change, which will increase the trading limit from 5% to 10% [8]. Group 3: Financial Performance Forecasts - Industrial Fulian expects a net profit increase of 36.84% to 39.12% year-on-year for the first half of 2025, driven by a surge in AI-related business [18]. - Huayou Cobalt anticipates a net profit increase of 55.62% to 67.59% for the same period, benefiting from integrated operations and rising cobalt prices [19]. - Guoli Co. forecasts a staggering net profit increase of 130.91% to 158.08% for the first half of 2025, attributed to new product and market expansions [20]. - Bangji Technology expects a net profit increase of 166.77% to 200.91%, driven by increased sales from direct sales channels [21]. - Lier Chemical predicts a net profit increase of 185.24% to 196% due to rising product sales and cost reduction efforts [25]. Group 4: Major Contracts and Projects - Huadian Science and Technology signed significant contracts worth approximately RMB 25.16 billion for coal handling and transportation systems [41]. - Aerospace Engineering is the first candidate for a project with a bid of RMB 23.92 billion for a coal gasification facility [43].

富士莱：公司拟2,000万元-4,000万元回购股份，资金来源为自有资金，回购价格不超过40元/股，回购 股份将在未来用于实施股权激励计划或员工持股计划。 ...

富士莱：拟使用2000万元-4000万元回购公司股份 智通财经7月7日电，富士莱(301258.SZ)公告称，公司拟使用自有资金不低于2000万元（含本数）且不 超过4000万元（含本数）通过集中竞价交易方式回购公司普通股（A股）股票，回购价格不超过40.00 元/股（含本数），未来适宜时机用于股权激励计划或员工持股计划。 ...

苏州富士莱医药股份有限公司（以下简称"公司"）第四届董事会第十九次会 议于 2025 年 7 月 7 日上午 10 时在公司会议室以通讯表决方式召开，会议通知 于 2025 年 7 月 1 日以邮件、电话、书面等方式通知全体董事。本次会议应出席 董事 7 人，实际出席董事 7 人。本次会议由董事长钱祥云先生召集并主持，公司 监事和高级管理人员列席了本次会议。会议的召集、召开及表决程序符合法律法 规及《公司章程》的有关规定。 一、议案审议情况 与会董事经过审议，以记名投票表决方式通过如下决议： （一）审议通过《关于使用自有资金回购公司股份方案的议案》 同意公司使用自有资金不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含本数）通过集中竞价交易方式回购公司普通股（A 股）股票，在 未来适宜时机用于股权激励计划或员工持股计划。回购价格不超过人民币 40.00 元/股（含本数）。 具体内容详见同日刊登在巨潮资讯网（www.cninfo.com.cn）的《关于使用自 有资金回购公司股份方案的公告》。 表决结果：7 票同意、0 票反对、0 票弃权。 证券代码：301258 证券简称：富士莱 公告 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-032 苏州富士莱医药股份有限公司 关于使用自有资金回购公司股份方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 1、回购股份的种类：苏州富士莱医药股份有限公司（以下简称"公司"或 "富士莱"）已在境内发行上市的人民币普通股（A 股）股票。 2、回购股份的用途：将在未来适宜时机用于实施股权激励计划或员工持股 计划。若公司未能在本次股份回购实施结果暨股份变动公告日后三年内使用完毕 已回购股份，尚未使用的已回购股份将依法予以注销。如国家对相关政策做调整， 则按调整后的政策执行。 3、回购股份的价格：不超过人民币 40.00 元/股（含）。该回购价格上限未 超过公司董事会审议通过回购股份决议前三十个交易日公司股票交易均价的 150%。若公司在回购期内发生派发红利、送红股、转增股本等除权、除息事项， 自股价除权、除息日起，相应调整回购价格上限。具体回购价格根据公司二级市 场股票价格、公司资金状况确定。 4、回购股份的数量、占公司总股本的比例：按回购价格上限 40.00 元/股和 回购 ...

监事会认为：本次回购公司股份方案的内容及审议程序符合《上市公司股份 回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》及 《公司章程》的相关规定，不会对公司经营、财务状况和未来发展产生重大不利 影响，不存在损害公司及股东利益的情形。因此，监事会同意本次回购公司股份 方案的具体事项。 具体内容详见同日刊登在巨潮资讯网（www.cninfo.com.cn）的《关于使用自 有资金回购公司股份方案的公告》。 表决结果：3 票同意、0 票反对、0 票弃权。 二、备查文件 证券代码：301258 证券简称：富士莱 公告编号：2025-031 苏州富士莱医药股份有限公司 第四届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第四届监事会第十八次 会议于 2025 年 7 月 7 日下午 3 时在公司会议室以通讯表决方式召开，会议通知 于 2025 年 7 月 1 日以邮件、电话、书面等方式通知全体监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席召集并主持。会议 ...